JP2004521867A5 - - Google Patents

Download PDF

Info

Publication number
JP2004521867A5
JP2004521867A5 JP2002537179A JP2002537179A JP2004521867A5 JP 2004521867 A5 JP2004521867 A5 JP 2004521867A5 JP 2002537179 A JP2002537179 A JP 2002537179A JP 2002537179 A JP2002537179 A JP 2002537179A JP 2004521867 A5 JP2004521867 A5 JP 2004521867A5
Authority
JP
Japan
Prior art keywords
antigen
dendritic cells
administering
cell
ncm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002537179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/048039 external-priority patent/WO2002034119A2/en
Publication of JP2004521867A publication Critical patent/JP2004521867A/ja
Publication of JP2004521867A5 publication Critical patent/JP2004521867A5/ja
Withdrawn legal-status Critical Current

Links

JP2002537179A 2000-10-27 2001-10-26 免疫抑制された患者のためのワクチン免疫療法 Withdrawn JP2004521867A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24391200P 2000-10-27 2000-10-27
PCT/US2001/048039 WO2002034119A2 (en) 2000-10-27 2001-10-26 Vaccine immunotherapy for immune suppressed patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008331616A Division JP2009102372A (ja) 2000-10-27 2008-12-25 免疫抑制された患者のためのワクチン免疫療法

Publications (2)

Publication Number Publication Date
JP2004521867A JP2004521867A (ja) 2004-07-22
JP2004521867A5 true JP2004521867A5 (cg-RX-API-DMAC7.html) 2005-04-21

Family

ID=22920630

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002537179A Withdrawn JP2004521867A (ja) 2000-10-27 2001-10-26 免疫抑制された患者のためのワクチン免疫療法
JP2008331616A Withdrawn JP2009102372A (ja) 2000-10-27 2008-12-25 免疫抑制された患者のためのワクチン免疫療法
JP2012020558A Expired - Lifetime JP5930742B2 (ja) 2000-10-27 2012-02-02 免疫抑制された患者のためのワクチン免疫療法
JP2013014029A Expired - Lifetime JP5963688B2 (ja) 2000-10-27 2013-01-29 免疫抑制された患者のためのワクチン免疫療法
JP2015089246A Withdrawn JP2015155446A (ja) 2000-10-27 2015-04-24 免疫抑制された患者のためのワクチン免疫療法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2008331616A Withdrawn JP2009102372A (ja) 2000-10-27 2008-12-25 免疫抑制された患者のためのワクチン免疫療法
JP2012020558A Expired - Lifetime JP5930742B2 (ja) 2000-10-27 2012-02-02 免疫抑制された患者のためのワクチン免疫療法
JP2013014029A Expired - Lifetime JP5963688B2 (ja) 2000-10-27 2013-01-29 免疫抑制された患者のためのワクチン免疫療法
JP2015089246A Withdrawn JP2015155446A (ja) 2000-10-27 2015-04-24 免疫抑制された患者のためのワクチン免疫療法

Country Status (7)

Country Link
US (8) US6977072B2 (cg-RX-API-DMAC7.html)
EP (1) EP1337149A4 (cg-RX-API-DMAC7.html)
JP (5) JP2004521867A (cg-RX-API-DMAC7.html)
AU (2) AU2002232560A1 (cg-RX-API-DMAC7.html)
CA (2) CA2464228C (cg-RX-API-DMAC7.html)
MX (1) MXPA03003638A (cg-RX-API-DMAC7.html)
WO (1) WO2002034119A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20060194242A1 (en) 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
DE10139965B4 (de) * 2001-08-14 2005-12-29 Biotest Ag Gammasterilisierbares Kulturmedium zum Nachweis von Hefen und Pilzen
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
US7342268B2 (en) * 2004-12-23 2008-03-11 International Business Machines Corporation CMOS imager with Cu wiring and method of eliminating high reflectivity interfaces therefrom
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080131396A1 (en) * 2006-12-04 2008-06-05 Cel-Sci Corp. Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
AU2008329741B2 (en) * 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
AU2009244617B2 (en) * 2008-04-14 2014-02-13 Irx Therapeutics, Inc. IRX-2 modified manufacturing process
EP2296704A4 (en) * 2008-05-29 2012-03-07 Irx Therapeutics Inc ACTION MECHANISM OF BIOLOGICAL MEANS FROM PRIMARY CELLS
EP2429585B1 (en) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Vaccine immunotherapy
JP5889797B2 (ja) 2009-12-08 2016-03-22 アイアールエックス セラピューティクス， インコーポレイテッド ランゲルハンス細胞の免疫抑制を逆転させる方法
WO2012037551A2 (en) * 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
US11712474B2 (en) * 2019-07-29 2023-08-01 Regen BioPharma, Inc. Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
US20220226465A1 (en) 2021-01-18 2022-07-21 ConserV Bioscience Coronavirus Immunogenic Compositions, Methods and Uses Thereof
CN112972669A (zh) * 2021-03-08 2021-06-18 河南道特尔医药科技股份有限公司 一种提高新冠疫苗对特殊人群抗体分泌的动物实验操作方法

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (cg-RX-API-DMAC7.html) * 1971-11-19 1975-02-07 Anvar
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4690623A (en) * 1978-05-31 1987-09-01 Karl Eickmann Fluid pumps, fluid motors and devices, which include a coned ring
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4470926A (en) * 1980-01-18 1984-09-11 Max-Planck-Gesellschaft zur F/o/ rderung der Wissenschaften e.V. Medicaments containing thymosin alpha 1 fragments and having an immunostimulant action, and fragments of thymosin alpha 1
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US4293455A (en) * 1980-04-07 1981-10-06 Rockefeller University N.sup.α -Desacetylthymosinα1 and process
IL62903A0 (en) 1980-05-22 1981-07-31 Deutsches Krebsforsch Method for the production of interferon ii and stimulated clones for the carrying out of the method
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4406830A (en) * 1981-04-17 1983-09-27 Shanksville Corporation, N.V. Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
DE3120912A1 (de) * 1981-05-26 1982-12-16 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von p-nitrophenetol
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4614731A (en) * 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4659694A (en) * 1983-10-27 1987-04-21 Hoffmann-La Roche Inc. Prothymosin alpha
US4716148A (en) * 1984-08-13 1987-12-29 Hoffman-La Roche Inc. Prothymosin alpha
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
AU7397887A (en) 1986-05-09 1987-12-01 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
SE8801426D0 (sv) 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
AU4525589A (en) * 1988-10-27 1990-05-14 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5225182A (en) * 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5503828A (en) 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
ZA934890B (en) * 1992-07-08 1994-04-14 Schering Corp Use of Gm-CSF as a vaccine adjuvant
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
WO1994029436A1 (en) 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
CN1044781C (zh) 1994-02-05 1999-08-25 丹东市生物制品免疫技术应用研究中心 复方免疫抗生素
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
ES2236719T3 (es) 1994-11-17 2005-07-16 University Of South Florida Metodo para fabricar un medicamento para el tratamiento de la inmunodeficiencia secundaria.
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
ATE244305T1 (de) 1995-05-04 2003-07-15 Us Gov Sec Navy Verfahren zur modulation der t-zell- überlebensrate durch von bcl-xl protein-spiegels
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CA2246359A1 (en) 1996-02-21 1997-08-28 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunization
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
CA2307345A1 (en) * 1997-10-17 1999-04-29 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
DK1053017T3 (da) * 1998-02-12 2004-11-22 Wyeth Corp Vacciner omfattende interleukin-12 og herpes simplex virusantigen
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
EP0974357A1 (en) 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
US6017537A (en) * 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6350589B1 (en) * 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
GB9903664D0 (en) * 1999-02-17 1999-04-14 Isis Innovation Adjuvant and cell maturation agent
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US7056503B2 (en) * 1999-08-19 2006-06-06 Regents Of The University Of Michigan Enclosures housing cell-coated supports for treating tumors
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
JP2004500095A (ja) * 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
KR20030015288A (ko) * 2000-06-22 2003-02-20 아메리칸사이아나미드컴파니 보조제 배합물로서의 큐에스-21 및 아이엘-12
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
US20060194242A1 (en) 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070154399A1 (en) 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
DE10154579A1 (de) * 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
CA2472578A1 (en) 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
WO2004056977A1 (en) 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
PL380269A1 (pl) * 2002-12-26 2007-01-08 Mountain View Pharmaceuticals, Inc. Koniugaty polimerowe cytokin, czynników wzrostu, hormonów polipeptydowych i ich antagonistów o zachowanej zdolności do wiązania receptora
EP1615661A2 (en) 2003-04-15 2006-01-18 Sanofi Pasteur Limited Tumor antigens bfa5 for prevention and/or treatment of cancer
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20070196335A1 (en) 2004-02-09 2007-08-23 The Johns Hopkins University Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells
GB0409799D0 (en) * 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
CA2568295A1 (en) 2004-06-04 2005-12-22 Cel-Sci Corporation A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
WO2005123120A1 (en) 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
US20060140983A1 (en) 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
AU2006292203A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
WO2007067782A2 (en) 2005-12-08 2007-06-14 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
US20070259330A1 (en) 2006-05-04 2007-11-08 Ge Healthcare Bio-Sciences Ab Separation of cells
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2008246149B2 (en) 2007-04-25 2013-09-12 Immurx, Inc. Adjuvant combinations of NKT activator, CD40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
GB2451928B (en) * 2007-06-21 2011-03-16 Angelica Therapeutics Inc Modified Toxins
AU2008329741B2 (en) * 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
AU2009244617B2 (en) 2008-04-14 2014-02-13 Irx Therapeutics, Inc. IRX-2 modified manufacturing process
EP2296704A4 (en) * 2008-05-29 2012-03-07 Irx Therapeutics Inc ACTION MECHANISM OF BIOLOGICAL MEANS FROM PRIMARY CELLS
EP2429585B1 (en) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Vaccine immunotherapy
JP5889797B2 (ja) 2009-12-08 2016-03-22 アイアールエックス セラピューティクス， インコーポレイテッド ランゲルハンス細胞の免疫抑制を逆転させる方法
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine

Similar Documents

Publication Publication Date Title
JP2004521867A5 (cg-RX-API-DMAC7.html)
JP2005510491A5 (cg-RX-API-DMAC7.html)
JP5930742B2 (ja) 免疫抑制された患者のためのワクチン免疫療法
Korbelik et al. Interaction Between Photodynamic Therapy and BCG Immunotherapy Responsible for the Reduced Recurrence of Treated Mouse Tumors¶
Mazzolini et al. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level
JP2009197032A (ja) 免疫抑制を逆転させるための免疫治療
JP2004534025A5 (cg-RX-API-DMAC7.html)
Bubenik et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
US5798090A (en) Enhancement of the cellular immune response
Kovalchin et al. Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96
Alfieri et al. Role of cell-mediated immunity in tumor eradication by hyperthermia
JP2001517208A (ja) 損傷した細胞ペプチドプロセッシングに関連する、例えばｂ７−１遺伝子で形質転換したｒｍａ−ｓ細胞上に発現される抗原またはエピトープの治療的応用
JP5254952B2 (ja) 日和見感染症の治療のための同種異系細胞治療
Grups et al. Cyclic interferon gamma treatment of patients with metastatic renal carcinoma
Richie et al. Current treatment of metastatic renal cell carcinoma with xenogeneic immune ribonucleic acid
Prehn et al. The flip side of tumor immunity
EP0313569B1 (en) Enhancement of the cellular immune response
JPH06199894A (ja) Ｃ型肝炎ウイルスのコア蛋白質領域に存在するｔ細胞エピトープ
Seshadri et al. Immunity stimulation and metastasis
WO2002072032A2 (en) Compounds and methods for identifying, staging and treating cutaneous t-cell lymphoma
CA1339494E (en) Enhancement of the cellular immune response
Hill et al. An in-situ neoadjuvant vaccination with IL-12 and GM-CSF in biodegradable microspheres with systemic IL-2 provides protection against metastatic disease.
CN116270990A (zh) Adam17在制备治疗效应性cd8+t细胞分化相关疾病药物中的用途
CN113440601A (zh) Nk细胞和tfpi联用在防治鼻咽癌中的应用